AEON Biopharma Regains NYSE American Listing Compliance

What Happened
AEON Biopharma, Inc. announced on August 3, 2026 that it has regained compliance with the continued listing standards of NYSE American. The company received a confirmation letter from NYSE Regulation stating it resolved the previously identified deficiencies and is now in compliance with the standards in Part 10 of the NYSE American Company Guide.

Key Details

• Date: August 3, 2026 — press release furnished as Exhibit 99.1 to the Form 8-K.
• Deficiencies resolved: Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide.
• Effect: NYSE American expects to remove the “.BC” (below compliance) indicator from AEON’s Class A common stock trading symbol and remove AEON from its public list of noncompliant issuers.
• Ongoing status: AEON remains subject to NYSE American’s continued listing standards and could face further action if it again fails to meet those standards.

Why It Matters
Restoring compliance removes a public “below compliance” marker that can affect trading perception and investor confidence. While this is a positive procedural milestone, AEON’s stock remains subject to the exchange’s rules going forward, so investors should note the company could be subject to further NYSE action if compliance lapses again.